Globus Medical Inc (GMED) · Aug 6, 2026 · Company update

Earnings beat and EPS guidance raise offset a modest revenue miss

Earnings beat and EPS guidance raise offset a modest revenue miss

The quarter beat on earnings but came in slightly light on revenue. Sales were $789.6 million versus published consensus of roughly $798.5 million, while non-GAAP diluted EPS was $1.34 versus expectations near $1.12.

MetricQ2 2026Q2 2025Market expectation
Net sales$789.6M$745.3M~$798.5M
Non-GAAP diluted EPS$1.34$0.86~$1.12
Adjusted gross margin69.4%67.4%—
Free cash flow$176.6M$31.3M—
Full-year revenue guidance$3.18B–$3.22B—Reaffirmed
Full-year non-GAAP EPS guidance$4.95–$5.05—Previously $4.70–$4.80

Underlying profitability was the stronger signal. Adjusted gross margin expanded 200 basis points to 69.4%, adjusted EBITDA margin rose to 35.4% from 28.0%, and free cash flow increased to $176.6 million from $31.3 million. That combination indicates the earnings outperformance was driven by operating leverage and cost discipline, not just accounting noise. (Adjusted EBITDA reconciliation; Adjusted Gross Profit table; Free Cash Flow table)

Growth was healthy but uneven. Total sales increased 5.9% year over year, with U.S. sales up only 3.0% and international sales up 18.0%, or 16.2% in constant currency. Musculoskeletal Solutions grew to $763.5 million, while Enabling Technologies fell to $26.1 million from $35.2 million. Management also reported 9% base-business growth excluding Nevro, but that figure is company-defined and not separately quantified in the financial tables. (Geographic Net Sales Growth; Segment Net Sales)

The guidance change makes the net read positive despite the top-line miss. Revenue guidance was unchanged, suggesting no major upgrade to demand expectations, but the midpoint of non-GAAP EPS guidance rose by about 5% to $5.00 from $4.75. The raise reflects better expected margins, operating leverage, and acquisition synergies; it is the clearest evidence that management believes the quarter's profitability improvement can persist. (Full-Year Guidance)

Net: a narrowly positive report. The revenue miss prevents this from being a clean beat, but the sizable adjusted EPS outperformance, margin expansion, stronger cash generation, and EPS guidance raise outweigh the modest top-line shortfall. GAAP EPS fell to $1.10 from $1.49 because the prior-year period included a $110.6 million Nevro bargain-purchase gain, making GAAP year-over-year comparisons less informative. (Income Statement; Non-GAAP Diluted EPS Reconciliation)

Original filing on SEC EDGAR

More Globus Medical Inc news

Earnings beat and EPS guidance raise offset a modest revenue miss | GMED Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.